ESL 800 mg

DRUG4 trials

Sponsors

Bial - Portela C S.A.

Conditions

EpilepsyFibromyalgiaMigrainePost Stroke Epilepsy

Phase 2

Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine

CompletedNCT01820559

Bial - Portela C S.A.Migraine

Start: 2009-04-30End: 2010-06-30Updated: 2013-05-24

Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia

CompletedNCT01820585

Bial - Portela C S.A.Fibromyalgia

Start: 2009-04-30End: 2010-09-30Updated: 2013-07-19

Anti-epileptogenic Effects of Eslicarbazepine Acetate

CompletedNCT06597084

Bial - Portela C S.A.Post Stroke Epilepsy

Start: 2019-05-29End: 2023-09-11Updated: 2025-05-02

Phase 3

Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures

CompletedNCT02484001

Bial - Portela C S.A.Epilepsy

Start: 2016-03-01End: 2018-09-11Updated: 2018-10-16

Related Papers

Lipid profile with eslicarbazepine acetate and carbamazepine monotherapy in adult patients with newly diagnosed focal seizures: <i><i>post hoc</i></i> analysis of a phase III trial and open-label extension study

Therapeutic Advances in Neurological Disorders2023-01-014 citations